Science 1997, 275:661–665.A-1210477 PubMedCrossRef 31. Gibson S, Tu S, Oyer R, Anderson SM, Johnson GL: Epidermal growth factor protects epithelial cells against Fas-induced apoptosis. Requirement for Akt activation. J Biol Chem 1999, 274:17612–17618.PubMedCrossRef
32. Koury MJ, Bondurant MC: Erythropoietin retards DNA breakdown and prevents programmed death find more in erythroid progenitor cells. Science 1990, 248:378–381.PubMedCrossRef 33. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100:57–70.PubMedCrossRef 34. Junnila S, Kokkola A, Mizuguchi T, Hirata K, Karjalainen-Lindsberg ML, Puolakkainen P, Monni O: Gene expression analysis identifies over-expression of CXCL1, SPARC, SPP1, and SULF1 in gastric cancer. Genes Chromosomes Cancer 2009, 49:28–39.CrossRef 35. Otsuki S, Taniguchi N, Grogan SP, D’Lima D, Kinoshita M, Lotz M: Expression of novel extracellular Repotrectinib datasheet sulfatases Sulf-1 and Sulf-2 in normal and osteoarthritic articular cartilage. Arthritis Res Ther 2008, 10:R61.PubMedCrossRef 36. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71–96.PubMedCrossRef Competing interests The authors
declare that they have no competing interests. Authors’ contributions CH participated in the study design and conducted the laboratory experiments, performed the statistical analysis, prepared figures, and tables and drafted the manuscript. YH performed the luciferase assay experiment in cell lines and participated the analysis and manuscript preparation. KHL provided patients’ samples and clinical information. ZL advised on designing primers and helped laboratory experiments. GBM supported the study, provided information on the study design and edited the manuscript. QW advised on study tuclazepam design, and revised the manuscript preparation, and supported the study. L-EW participated in the study design, oversaw the entirety of the project and assisted in the analysis and the manuscript preparation. All authors
read and approved the manuscript.”
“Introduction Despite recent improvements, the prognosis of patients with peritoneal carcinomatosis from digestive or ovarian origin treated with systemic chemotherapy remains poor [1, 2]. Intraperitoneal chemotherapy (IPC) improves the control of regional disease in ovarian cancer and increases survival in carcinomatosis of colorectal origin [3, 4]. Trials have shown a survival benefit with post-operative IPC versus intravenous administration of cisplatin-based chemotherapy in ovarian cancer [5, 6]. However, post-operative IPC showed poor tolerance and reduced quality of life in comparison with standard systemic chemotherapy . Intraoperative IPC after cytoreductive surgery is a widely used alternative which achieves good results [7–9]. However, the best method for IPC has not yet been determined [10, 11].